In a dual-center study comprising 7,246 COVID-19 patients, including 12 with Down syndrome, levels of inflammation markers, such as C-reactive protein and IL-6, were not much different between 12 patients with Down syndrome and 60 patients without, but the Down syndrome patients had more severe disease (29). This evidence concerns the gene CRP and Down syndrome.